Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04949191
Title The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | DNK

Facility Status City State Zip Country Details
John Wayne Cancer Institute Santa Monica California 90404 United States Details
Oncology Specialists of Charlotte Charlotte North Carolina 28207 United States Details
Md Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research Therapeutics San Antonio Texas 78229 United States Details
Virginia Cancer Specialists, Pc Fairfax Virginia 22031 United States Details
The Finsen Centre National Hospital Copenhagen 02100 Denmark Details
Fondazione Irccs Istituto Nazionale Dei Tumori Milan 20133 Italy Details
Istituto Nazionale Tumori Regina Elena Irccs Rome 00144 Italy Details
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte Siena 53100 Italy Details
Kanagawa Cancer Center Yokohama-Shi 241-8515 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field